Newbury Pharmaceuticals expands the team with a Head of Business Development
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Pressmeddelande

Newbury Pharmaceuticals expands the team with a Head of Business Development

Newbury Pharmaceuticals is pleased to announce the appointment of Mrs. Andrea Karnitschky as Senior Director and Head of Business Development. From August 1st 2022, Andrea Karnitschky’s responsibilities include the expansion of the pipeline and the development of strategic partnerships.

We are very pleased to strengthen our team with Andrea who has an impressive track record in deal making. Andrea will be an important addition to Newbury, and I look forward to the collaboration to further grow our strong pipeline with new products and new exciting business opportunities”, says Lars Minor, CEO, Newbury Pharmaceuticals.

Prior to joining Newbury, Andrea Karnitschky held a position as Director & Head of In-licensing Europe at Dr. Reddy´s Laboratories SA following an appointment as Head of Sourcing at betapharm Arzneimittel GmbH. Andrea Karnitschky has a broad and deep network within the global pharmaceutical industry.

“I am excited to join Newbury – a young, dynamic, entrepreneurial company with high ambitions. It will be an interesting challenge to contribute to the growth of Newbury.” says Andrea Karnitschky.

Bifogade filer

Nyheter om Newbury Pharmaceuticals

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!

STÄNG X
Populär sparapp – över 500 000 nedladdningar
Många och höga externa omdömen
Högst grad av diversifiering
Perfekt för regelbundet månadssparande
KOM IGÅNG

Nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 får automatiskt 50 procent rabatt på Optis avgift i 3 månader

Om aktien Newbury Pharmaceuticals

Senaste nytt